Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine vs Hydroquinone for Melasma
NCT06957834Phase 2Completed
- Sponsor
- National Skin Centre
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eflornithine in melasma (2 arms), sponsored by National Skin Centre. Primary endpoints: Modified Melasma Area and Severity Index at 12 weeks and Mexameter Melanin Score at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
eflornithine
03
Conditions
melasma
Beyond the preview
Go deeper on NCT06957834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957834.